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Biomarkers of disease activity in secondary progressive MS are scarce. YKL-40 is a glycoprotein predominantly 
produced by reactive astrocytes in chronic active lesions and is readily detected in cerebrospinal fluid. Thus 
YKL-40 could be a good biomarker to monitor disease activity in secondary progressive MS. 
Methods 
YKL-40 levels in cerebrospinal fluid samples from two independent patient cohorts of MS patients were 
determined together with two other potential biomarkers of astrocyte and microglia activation (GFAp and 
sCD14). Patients from one of the cohorts underwent MRI investigation as well.  
Results 
YKL-40 levels were overall higher in MS patients than in controls, particularly in secondary progressive MS 
patients and patients with relapse, whereas relapsing-remitting MS patients in remission had levels 
indistinguishable from controls. The number of T1, T2 and gadolinium enhancing lesions correlated with the 
levels of YKL-40, whereas the signal intensity of normal appearing white matter was inversely related to YKL-40. 
No statistically significant differences between the levels of GFAp and sCD14 in MS patients versus controls were 
detected, but these correlated moderately with YKL-40, and GFAp correlated strongly with measures of atrophy. 
Conclusions 
YKL-40 levels in CSF are increased in secondary progressive MS. YKL-40 is a promising biomarker for 
therapeutic effect of drugs targeting CNS inflammation in secondary progressive MS. 
 




Multiple sclerosis (MS) is an autoimmune disease of the central nervous system. At onset, 85% of patients will 
have a relapsing remitting form (RRMS), with periods of worsening followed by periods of recovery and stable 
disease. Eventually, most patients will develop a secondary progressive form (SPMS), characterized by fewer and 
milder relapses (1, 2), less radiological activity (3, 4), but continuous deterioration of neurologic function (5). 
Treatments targeting adaptive immunity have largely been unsuccessful in SPMS (6) and at present there is no 
effective therapy for SPMS. 
The cause of SPMS is unknown. The copious treatment failures with anti-inflammatory drugs tell us that if 
inflammation is still important to the pathogenesis of SPMS, it must be of a fundamentally different form. 
Chronically active white matter lesions are thought to be characteristic of progressive forms of MS. They contain 
a demyelinated core with few T cells, which is surrounded by a rim of microglia nodules and enlarged astrocytes 
(7, 8). This type of lesion is also called slowly expanding lesion and is believed to increase in size over time, 
contributing to demyelination and axonal damage.  
YKL-40 (also known as chitinase 3-like-1 or CHI3L1) is a member of the chitinase-like glycoprotein family and is 
predominantly produced by reactive astrocytes (9, 10). In brain tissue from MS patients, YKL-40 is expressed in 
reactive astrocytes and microglia at the rim of chronically active lesions (10). The physiological role of YKL-40 is 
not known, but it has been hypothesized to be involved in tissue remodeling during inflammation (9). Increased 
levels have been found in CSF from patients with clinically isolated syndrome (CIS) and MS (9-15).  
The purpose of this study was to further characterize YKL-40 in different stages of MS; to investigate the relation 
between YKL-40 and other biomarkers of astrocyte and microglia activation; and to explore its potential as a 
biomarker of inflammation in SPMS.  
Materials and methods 
Ethics statement 
The study was approved by the ethics committees of Uppsala University (DNr 2008/182) and Gothenburg 
University (EPN S589-03, EPN S464-97). All subjects provided written informed consent. 
Subjects 
  
Subjects were prospectively recruited from two university hospitals in Sweden. Cohort A (n=62) was recruited at 
Uppsala University Hospital. Cohort B (n=65) comprised patients from Sahlgrenska University Hospital, 
Gothenburg, and has been described previously (13). 
Cohort A 
Sixty-two MS patients were included in cohort A: 27 RRMS patients in remission, 15 RRMS patients with a 
clinical relapse and 20 with SPMS. All patients met the revised McDonald’s criteria for MS diagnosis (16). A 
clinical relapse was defined as new or recurrent neurologic symptoms lasting ≥24 hours, not associated with 
fever or infection. Relapses were assessed by an experienced neurologist (JB), who also performed all expanded 
disability status scale (EDSS) scoring (17). SPMS patients were clinically deteriorating in the absence of clinical 
relapses. No transitional cases of SPMS were included. Five patients with a clinical relapse were investigated 
twice, in remission and in relapse. The characteristics of subjects are summarized in Table 1. 
To identify inflammatory disease activity, MRI of the brain was performed. All but six patients underwent MRI of 
the entire spinal cord as well. A lumbar puncture was made within one week of the MRI. Following lumbar 
puncture, CSF was stored in polypropylene tubes stored at -80°C without being thawed and re-frozen. Twenty 
RRMS patients were on treatment (glatiramer acetate, n=8; beta interferon, n=6; IVIG, n=4; natalizumab, n=2) 
and two SPMS patients (interferon beta, n=1; natalizumab, n=1). No patient was treated with corticosteroids 
within one month of sampling. 
Cohort B 
Cohort B consisted of 11 RRMS patients in remission, 29 RRMS patients with a clinical relapse, and 15 SPMS 
patients CSF was collected by lumbar puncture before immunomodulatory treatment. MRI data were not 
available from patients in cohort B. 
Controls 
Thirty healthy volunteers were recruited as controls. They underwent only lumbar puncture. 
Enzyme-linked immunosorbent assays 
All samples were analyzed in the same laboratory by board-certified laboratory technicians who were blinded to 
clinical data. CSF levels of YKL-40 and sCD14 were analyzed with commercial ELISAs (R&D systems, 
Minneapolis, MN). The intra-assay CV was 4.6% and the inter-assay CV was 6.0% for YKL-40. The limit of 
detection was 3.55 pg/ml. GFAp was analyzed with a previously described ELISA (18).  
  
Acquisition of images 
All MRI investigations were performed with the same imager operating at 1.5 T using the same imaging protocol. 
Gadopentetate dimeglumine (Magnevist®, 0.4 ml/kg body weight, i e double dose) was used as a contrast agent. 
Technical details regarding the MRI investigations are found in the supplementary section. 
Analysis of images 
Technical details regarding the MRI investigations are available in the Appendix. An experienced neurologist (JB) 
and a senior neuroradiologist (RR) analysed all MR images visually. T2 lesions >3 mm in diameter were counted 
in fluid attenuated inversion recovery images using T2-weighted and proton density-weighted spin echo images 
as aid. The width of the third ventricle was measured in coronal projections of the cerebrum. The sizes of the 
lateral ventricles and peripheral cerebral CSF spaces on each side were graded from one to five according to a 
method described previously (19). In order to assess tissue damage not visible to the naked eye, signal 
intensities in normal appearing white matter (NAWM) were measured by the neuroradiologist in T2-weighted 
SE images. Measurements were made in one slice traversing the cerebrum and in another slice traversing the 
cerebellum and pons. In the cerebrum, the regions of interest were placed in the frontal lobe anterior to the 
frontal horn, in deep white matter near the atrium of the lateral ventricle, and in the base of a lower parietal 
gyrus. In the other slice, the ROIs were placed in the cerebellum in close proximity to the middle cerebellar 
peduncle and in the anterior pons. The intention was to normalize the measured SIs of ROIs to the SIs of the 
references in the same slice. However, the references were not always optimally placed and could not be used in 
all slices selected for measurements. Assessment of NAWM with this method could be made in 37/64 
examinations using the oil reference and 42/64 examinations using the water reference. 
Statistical analysis 
Statistical analyses were done with GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA) and SAS 9.3 (SAS 
Institute, Cary, North Carolina, USA). Baseline characteristics were summarized by MS subtype using frequencies 
for categorical variables and medians with interquartile intervals for continuous variables. To determine 
statistically significant differences between two groups, the Mann-Whitney test was used; for statistical 
significance between three or more groups the Kruskal-Wallis test. Dunn’s multiple comparison test was used for 
post hoc analysis. Correlations were described with Spearman's rank correlation coefficient. An ANCOVA model 
with the natural logarithm of YKL-40 as dependent variable and MS subtype and age as independent variables 
was used. Pairwise comparisons were performed using Tukey’s method. Geometric means were calculated using 
  
the antilogs of the model-adjusted means of the log transformed YKL-40 levels. A two-tailed p value of < 0.05 was 
considered significant. All described differences are statistically significant unless otherwise stated. 
Results 
Results from analyses of Cohort A 
MRI findings 
All patients with a clinical relapse had a least one gadolinium enhancing (Gd+) lesion on T1 sequences. In 
addition nine RRMS patient in remission had subclinical inflammatory activity with at least one Gd+ lesion. 
These patients were grouped together in the subsequent analyses. The results of the analysis of the MRI 
measurements are summarized in Supplementary table 3 of the Appendix. 
YKL-40 in relation to clinical data 
SPMS patients as well as RRMS patients with Gd+ lesions had increased levels of YKL-40 in comparison to RRMS 
patients in remission and controls (Fig 1A). Patients in relapse had higher levels than when the same patients 
were examined in remission (Fig 1B). SPMS patients with Gd+ lesions (n=3) had higher values than other SPMS 
patients (mean 257 vs 146 ng/mL) but due to the small number of patients in this group, no statistical analysis 
was made. YKL-40 correlated with EDSS scores (Spearman r=0.32, p=0.0089, but not with disease duration. A 
strong correlation with age was found when the controls were examined separately (Spearman r=0.68, p < 
0.0001). Therefore, an age-adjusted analysis was made. After correction for age, YKL-40 values from the SPMS 
group were no longer different with statistical significance from RRMS patients in remission. 
YKL-40, GFAp and sCD14 in relation to MRI data 
In order to determine the relationship between YKL-40, GFAp and sCD14 vis-a-vis ongoing inflammation, 
manifest tissue damage and tissue damage in NAWM a set of correlation analyses was made (Table 2). YKL-40, 
but not GFAp and sCD14, was correlated with the number of Gd+ lesions and accordingly YKL-40 levels were 
higher in patients with more Gd+ lesions (Figure 1C). For the subsequent analyses, patients with Gd+ lesions 
were excluded in order to remove the influence of acute inflammation. YKL-40 correlated with the number of T1 
lesions, T2 lesions and atrophy of cerebral sulci. In addition, YKL-40 was negatively correlated with the SI of 
NAWM. GFAp correlated with the number of T1 and T2 lesions as well as all measures of atrophy. No significant 
correlation was seen between the levels of sCD14 and any MRI parameter. 
  
Results from the combined cohorts 
Results of analyses of YKL-40 and sCD14 in cohort B have been reported previously (13). The levels of YKL-40 
were higher in MS patients from the combined cohorts (A + B) than in controls (median 121 vs 82.0, p < 0.0001). 
For the subsequent analyses, RRMS patients with presence of Gd+ lesions from Cohort A were analyzed together 
with patients with clinical relapse from Cohort B and patients with RRMS and no Gd+ lesions from Cohort A were 
analyzed together with RRMS patients in remission from Cohort B. After an age-adjusted analysis, SPMS patients 
had higher YKL-40 levels than controls. In addition, patients with Gd+ lesions and clinical relapse had increased 
levels of YKL-40 in comparison with RRMS patients in remission and controls (Figure 1D). The levels of YKL-40, 
GFAp and sCD14 correlated with each other to a similar degree (Table 3). GFAp in MS patients was not different 
from controls (321 vs 290 pg/mL, p=0.34); nor was sCD14 (84,7 vs 98,5 ng/mL, p=0.11). 
Discussion 
We have previously reported that YKL-40 is increased in the CSF from MS patients (13). Our main finding in this 
study is that YKL-40 is elevated in CSF from SPMS patients, similar to the level of RRMS patients with relapse. 
This finding supports that astrocyte-microglia interactions are important to the pathogenesis of SPMS and that 
inflammation remains important in this chronic phase of the disease. Since other biomarkers of inflammation 
such as presence of Gd+ lesions or intrathecal production of chemokines are generally absent or low-grade in 
SPMS (3, 4, 20), this is consistent with the idea of compartmentalized inflammation. 
For the purposes of this study we propose a model where the mechanism of increased YKL-40 production is 
fundamentally different in the different stages of MS. In the early stages of RRMS, increase in YKL-40 production 
would be dependent on the presence of acute lesions, which can be determined in vivo by MRI investigation with 
administration of a contrast agent such as gadolinium. In this setting, YKL-40 production should be low in 
patients while in biological remission (i.e. no clinical relapse and absence of Gd+ lesions at MRI investigation) 
and high in patients with a biological relapse. With the accumulation of chronically active lesions, leading to the 
phenotype of SPMS, the baseline level of YKL-40 should increase, reflecting low-grade inflammation in these 
lesions, ultimately leading to tissue damage and disability.  
This model is supported by data from several studies. In vivo, YKL-40 is found in the soma of astrocytes in the 
vicinity of microglial nodules (21). It has been demonstrated that YKL-40 mRNA is expressed by reactive 
astrocytes surrounding microglial nodules suggesting that macrophages induce YKL-40 expression in 
  
surrounding astrocytes (9). In the Gd+ lesion massive infiltration of macrophages/microglia is seen together 
with reactive astrocytes, whereas in chronic inactive lesions microglia are sparse (22). Further, microglial 
nodules are found in white matter bordering chronically active lesions from SPMS patients where ongoing 
demyelination is present (7, 8) - when absent, demyelination and axonal degeneration are similar to age-
matched controls (8). In vivo, SPMS patients have on average more activated microglia in T1 lesions than RRMS 
patients (23). Lastly, increased levels of YKL-40 in the CSF from MS patients confer an increased risk of 
progression to EDSS 3 and 6 (14). 
Our data are supportive of this model. We have previously shown that YKL-40 is increased in all MS patients, 
regardless of subtype (13). In this study, with the addition of MRI data, we were able to further refine this 
analysis. RRMS patients in remission without Gd+ lesions had YKL-40 levels indistinguishable from controls. 
Notably, three outliers had clearly elevated levels, which may represent subclinical relapses with CNS 
inflammation that were not detected by MRI or incipient SPMS (Figure 1A). Patients in clinical relapse and/or 
with Gd+ lesions displayed increased levels of YKL-40. The dynamic fluctuation of YKL-40 in RRMS is further 
reinforced by the finding that YKL-40 levels decreased with repeated investigation when patients were 
investigated in remission (Figure 1B) and our previously reported finding that YKL-40 levels decrease with 
immunotherapy (13). When we increased the sample size by combining cohort A and B, we could confirm that 
the levels of YKL-40 were increased in SPMS as well (Figure 1D). This finding challenges the prevailing view that 
inflammation is unimportant to the pathogenesis of SPMS, but is very much in line with the recently published 
study from Komori et al, who reported that markers of B and T cell activation were present in the CSF from 
RRMS patients and SPMS patients to a similar degree (24). 
To investigate YKL-40 in relation to tissue damage a series of correlation analyses were performed. To remove 
the effect of acute inflammation, we excluded subjects with Gd+ lesions from the analysis. It is well known that 
T1 lesions may evolve into black holes, which probably is the MRI correlate of a chronic active lesion (23). We 
found that the T1 lesion load correlated with YKL-40, suggesting that this biomarker may reflect on-going low 
grade inflammation in such areas. In contrast, classical inflammation driven demyelination is largely absent in 
the NAWM where instead prominent axonal degeneration is present in SPMS patients (25). Several methods 
have been used to estimate the integrity of NAWM. In this study, we measured the SI of NAWM in T2 weighted 
images and normalized the SI against two external references containing either oil or water. A high normalized 
SI represents increased water content in the NAWM, reflecting tissue damage not visible to the naked eye. We 
found an inverse relation between the SIs and the levels of YKL-40. Thus our data suggest a fundamental 
  
difference to the origin of tissue damage in T1 lesions vis-a-vis NAWM. This is consistent with a dual paradigm 
where both inflammation and degeneration are important to the development of tissue damage and disability in 
SPMS.  
We also investigated how YKL-40 related to other biomarkers of astrocyte and microglia activation. GFAp is the 
principal intermediate filament in mature CNS astrocytes. GFAp is thought to be important in modulating 
astrocyte motility and shape by providing structural stability to astrocytic processes. Following tissue injury, 
astrocytes become reactive and respond with rapid synthesis of GFAp (26). GFAp is an established biomarker of 
astrogliosis and moderately elevated levels of GFAp have previously been demonstrated in patients with 
progressive MS (27-30). CD14 is abundantly found on macrophages and monocytes, but also exists in a soluble 
form (sCD14), which either appears after shedding of membrane bound CD14 or is directly secreted from 
intracellular vesicles (31). Increased levels of sCD14 in serum have been demonstrated in stable RRMS and SPMS 
patients (32, 33), whereas we recently reported that the levels of sCD14 in CSF from MS patients were similar to 
healthy controls (13). 
In difference to YKL-40, GFAp and sCD14 did not correlate with the number of Gd+ lesions, suggesting that the 
levels of these biomarkers are independent of acute inflammation. Since YKL-40 is believed to be dependent on 
both astrocyte and microglia activation, we expected to find a correlation between the levels of YKL-40 and GFAp 
as well as sCD14. Again, to remove the effect of acute inflammation, we excluded subjects with Gd+ lesions from 
the analysis. YKL-40, GFAp and sCD14 were all correlated with each other to a similar degree (Table 3). GFAp 
correlated well with measures of atrophy and to a lesser extent with T1/T2 lesions, but not convincingly with SIs 
of NAWM. Most likely this is reflecting lesion dependent astrogliosis in the CNS. Somewhat unexpectedly, no 
significant correlation was found between any MRI parameter and sCD14. Since the levels of sCD14 were also 
similar between MS patients and controls, the value of sCD14 as a biomarker in MS is questionable at best. A 
possible explanation to the negative findings is that sCD14 is predominantly produced in the periphery with 
more than tenfold higher concentration in serum in comparison to CSF (13, 34) and the levels of sCD14 in CSF 
might be influenced by passive transfer over the blood-brain barrier. 
Overall, our results are in concordance with previous studies. Several previous investigators have reported YKL-
40 to be increased in the CSF from MS or CIS patients (9-15). Two studies reported that YKL-40 correlated with 
the number of Gd+ lesions to a similar degree as in the present study (10, 11), while another failed to detect a 
correlation, most likely due to the low number of enhancing lesions in the cohort. YKL-40 in SPMS has been less 
  
studied. In one study YKL-40 levels in SPMS were similar to healthy controls (11), which is seemingly at odds 
with the findings from the present study. The reason for this discrepancy is unclear, but may reflect underlying 
differences in the composition of the studied cohorts.  
Conclusion 
Several biomarkers are available to monitor disease activity in RRMS, but biomarkers of SPMS are few and far 
between. We have demonstrated that the YKL-40 level is elevated in CSF from SPMS patients, that YKL-40 
correlates with the number of T1 lesions and is inversely correlated with the SI of NAWM. This suggests that the 
CSF level of YKL-40 in SPMS is reflecting the number of chronic active lesions. Such lesions probably contribute 
significantly to the development of disability in SPMS patients and thus YKL-40 should be a good biomarker to 
monitor disease activity in SPMS. 
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Table 1. Clinical and demographical data of Cohort A. 
  Controls Gd- RRMS Gd+ RRMS SPMS 
n 30 18 24 20 
Female/Male 8/22 12/6 16/8 11/9 
Age (IQR) 40 (36-52) 39 (34-45) 38 (25-44) 59 (54-66) 
EDSS (IQR) n/a 2.0 (1.5-2.0) 2.0 (1.0-2.9) 5.8 (3.6-6.0) 
Disease duration (IQR) n/a 9.6 (7.5-20) 4.7 (0.20-7.0) 23 (14-29) 
On treatment n/a 10/18 10/24 2/20 
  
Gd-, not enhancing gadolinium; Gd+, gadolinium enhancing; RRMS, relapsing-remitting multiple sclerosis; SPMS, 
secondary progressive multiple sclerosis; EDSS, expanded disability status scale. Age (years), EDSS and disease 




Table 2. Correlations between biomarkers of astrocyte and microglia activation and MRI parameters. 
    GFAP YKL-40 sCD14 
 n r p-value R p-value r p-value 
Gd+ 62 -0.18 0.15 0.33 0.0097 -0.080 0.54 
T1 35 0.52 0.0013 0.44 0.0071 0.18 0.18 
T2 35 0.52 0.012 0.35 0.039 0.090 0.61 
Atrophy third ventricle 35 0.66 <0.0001 0.27 0.12 0.0007 1.0 
Atrophy lateral ventricle 35 0.58 0.0004 0.28 0.11 0.13 0.47 
Atrophy cerebral sulci 35 0.70 <0.0001 0.37 0.030 0.051 0.77 
NAWM cerebrum - oil  29 0.28 0.14 -0.21 0.27 -0.20 0.29 
NAWM cerebrum - water 33 0.074 0.68 -0.45 0.0094 -0.34 0.051 
NAWM pons and cerebellum - oil 29 -0.0022 0.99 -0.41 0.027 -0.35 0.065 
NAWM pons and cerebellum - water 30 -0.42 0.020 -0.38 0.041 -0.34 0.067 
 
MRI, magnetic resonance imaging; GFAp glial fibrillary acidic protein; Gd+, gadolinium enhancing; NAWM, 
normal appearing white matter; Significant correlations in bold face. Patients with Gd+ lesions were excluded 
from the correlation analysis of the parameters below the double line. 
  
  
Table 3. Correlations between YKL-40, GFAp and sCD14. 
  GFAp YKL-40 sCD14 
 Spearman r p-value Spearman r p-value Spearman r p-value 
GFAp     0.43 0.00053 0.48 0.00012 
YKL-40 0.43 0.00053   0.60 < 0.0001 
sCD14 0.48 0.00012 0.60 < 0.0001     




Figure 1. YKL-40. 
 
Gd-, not enhancing gadolinium; Gd+, gadolinium enhancing; RRMS, relapsing-remitting multiple sclerosis; SPMS, 
secondary progressive multiple sclerosis. A) Unadjusted levels of YKL-40 in healthy controls and patients in 
different stages of MS from cohort A. Each dot represents one individual. B) YKL-40 levels in five RRMS patients 
sampled in relapse and remission. C) Levels of YKL-40 in RRMS patients with Gd+ lesions (median with IQR). D) 
Age adjusted analysis of differences in YKL-40 levels in patients from the combined cohorts (geometric mean 
with 95 % CI). 
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